1st Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Firm
Client
Income
—
Expenses
$446,324
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

Reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417)

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ New —
THOMAS B SPARKMAN —
SUSAN VAN METER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ —
THOMAS B SPARKMAN —
SUSAN VAN METER —

Contacted: Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; SENATE

Bills named: H.R. 2369 (118th), S. 1000 (118th), H.R. 2377 (118th)

Medicare/Medicaid MMM

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); access to clinical laboratory services pursuant to a telehealth visit Saving Access to Laboratory Services Act H.R. 2377/S. 1000,

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ —
THOMAS B SPARKMAN —
SUSAN VAN METER —

Contacted: SENATE; White House Office; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 1000 (118th), H.R. 2377 (118th)

Budget/Appropriations BUD

Policies related to diagnostics and laboratory regulation

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ —
THOMAS B SPARKMAN —
SUSAN VAN METER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ —
THOMAS B SPARKMAN —
SUSAN VAN METER —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); White House Office; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 2377 (118th), H.R. 2369 (118th), S. 1000 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.